Combined chemo-radiation and hyperthermia for locally advanced soft tissue sarcoma: response and toxicity

Anticancer Res. 1995 Nov-Dec;15(6B):2655-7.

Abstract

Background: Evaluation of the primary effects and acute adverse reactions of combined chemo-radiation and hyperthermia for patients with locally advanced soft tissue sarcoma.

Materials and methods: Eight patients with locally advanced soft tissue sarcoma underwent a combination of radiation therapy, continuous infusion of doxorubicin, and once weekly hyperthermia.

Results: Complete response was obtained in 2 patients and partial response in 3. Level 4 skin reaction was developed in 4 patients who had superficially located tumour. Treatment interruption more than three days was required in only one patient who developed level 4 pharyngitis. Five patients developed grade 3 leukopenia, 2 had grade 4 leukopenia requiring administration of haematopoietic growth factor. Two patients developed radiation pneumonitis which required steroid medication. No symptomatic cardiotoxicity was observed. There was no acute morbidity during the treatment.

Conclusions: The intensive combination therapy provided good local responses or at least palliation for most of the patients entered without increasing treatment morbidity.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Combined Modality Therapy
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Doxorubicin / therapeutic use*
  • Feasibility Studies
  • Female
  • Humans
  • Hyperthermia, Induced*
  • Infusions, Intravenous
  • Leukopenia / chemically induced
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / therapy
  • Palliative Care*
  • Radiation Pneumonitis / etiology
  • Sarcoma / drug therapy
  • Sarcoma / pathology
  • Sarcoma / radiotherapy
  • Sarcoma / therapy*
  • Soft Tissue Neoplasms / drug therapy
  • Soft Tissue Neoplasms / pathology
  • Soft Tissue Neoplasms / radiotherapy
  • Soft Tissue Neoplasms / therapy*
  • Treatment Outcome

Substances

  • Doxorubicin